CN Bio Innovations Marks World Hepatitis Day by Signing Research
Agreement with Imperial College London

Collaboration will develop and further validate CN Bio’s in vitro
model of Hepatitis B liver infection

July 28, 2014 09:00 AM Eastern Daylight Time

OXFORD, England--(BUSINESS WIRE)--CN Bio Innovations Ltd (CN Bio), an expert in developing leading edge
human biomimetic platforms to test and develop therapeutics for serious
diseases, announced today that it has signed a research agreement with
Imperial College London to advance the development of in vitro
models of liver infection based on the company’s LiverChip™ platform.
The announcement coincides with the WHO
World Hepatitis Day and serves to further emphasise the current
efforts being forged by industry and academia to find cures for
Hepatitis and other serious liver diseases.

Validation of in vitro system for liver infection

Dr Marcus Dorner, who is the Lead Principal Investigator on the new
project at Imperial, commented: “Unfortunately, the liver models
currently in widespread use often fail to accurately reproduce what we
see in vivo, limiting their utility.” He continued: “We’re excited about
the early potential shown by CN Bio’s platform for studying the
pathology of Hepatitis B and look forward to presenting our results from
this ongoing program of work at a number of international conferences
this Fall.”

Forging enabling partnerships and alliances with Academia and Industry

Dr Emma Sceats, COO at CN Bio, said: “We are pleased to extend our
relationship with Imperial through this new collaboration with Dr Dorner
and Professor Mark Thursz. Forging partnerships with key opinion leaders
and academic groups is a cornerstone of our research and development
strategy whose goal is to bring to market biomimetic models that will
provide unique insights into liver biology and disease pathology.
Through alliance partnerships with major pharmaceutical and biotech
companies, CN Bio’s experts are using these models to accelerate the
development of drugs that will provide life-changing treatment and cures
for patients affected by serious liver diseases.”

CN Bio Innovations (CN Bio), formerly Zyoxel Ltd, is part of the Hong
Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human
biomimetic platforms for the testing and development of therapeutics for
serious human diseases. Working closely with academic pioneers in the
bio-engineering field, CN Bio is developing next generation tissue and
disease models which will improve the quality of life for millions of
people around the world by fast tracking breakthrough therapies to
market.